Podcasts about screenings

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Ian Gardner, founder and CEO of The Acraya, about dark retreats as an ancient contemplative practice now entering Western culture. This episode is sponsored by The Acraya. Listeners of The Psychedelic Podcast can receive 5% off an Acraya retreat. Visit https://acraya.global/thirdwave and use discount code 3WAVE when booking. Ian explains what happens when external stimulation disappears, why boredom and difficult inner material can become central parts of the experience, and how dark retreats compare with psychedelics and extended meditation. He also discusses screening, facilitator training, post-retreat integration, and his vision for technologically supported retreat centers in Costa Rica, Nepal, Bali, and beyond. Episode Highlights: Ancient roots of dark retreat practice What remains when sensory anchors disappear Psychedelics versus gradual inner awakening Boredom as a gateway to deeper material Preparing for several days in darkness Why facilitators need embodied experience Screening for psychological contraindications Technology designed to support retreat safety Integrating before returning to ordinary life Scaling dark retreat centers worldwide Ian Gardner is the founder and CEO of The Acraya, a network of dark meditation retreat sanctuaries. A seasoned entrepreneur, he has founded and exited five companies across biotechnology, renewable energy, and electric vehicles in private and public markets. While earning his MBA from the University of California, Los Angeles, Ian was introduced to yoga and meditation. He later explored Transcendental Meditation, Self-Realization Fellowship, Eckankar, Mudrashram, and the Bridge Path. In 2001, he traveled to Allahabad, India, for the Maha Kumbh Mela before entering a year of seclusion, during which he meditated for up to eight hours daily. Ian has written six books related to esoteric teachings and spent two years working at the Esalen Institute. In 2023, he founded the Church of the Acraya to support the development of dark meditation retreat centers worldwide. He lives in Scottsdale, Arizona, with his wife and children and maintains a daily meditation practice. Epoisode Links: Explore The Acraya and receive 5% off with code 3WAVE Additional Episode Sponsors: The Psychedelic Practitioner Certification by Third Wave's Psychedelic Coaching Institute. Golden Rule - Get a lifetime discount of 10% with code THIRDWAVE at checkout Find full show notes and links here: https://thethirdwave.co/podcast/episode-367/?ref=278 Third Wave occasionally partners with or shares information about other people, companies, and/or providers. While we work hard to only share information about ethical and responsible third parties, we can't and don't control the behavior of, products and services offered by, or the statements made by people, companies, or providers other than Third Wave. Accordingly, we encourage you to research for yourself, and consult a medical, legal, or financial professional before making decisions in those areas. Third Wave isn't responsible for the statements, conduct, services, or products of third parties. If we share a coupon code, we may receive a commission from sales arising from customers who use our coupon code. No one is required to use our coupon codes." Disclaimer: This episode is provided for educational and entertainment purposes only and should not be considered medical, psychological, or legal advice. Any views, experiences, or claims expressed by the guest are his own and do not necessarily represent those of Third Wave or The Psychedelic Podcast.

TODAY ON THE ROBERT SCOTT BELL SHOW: RFK Takes On CNN, Deadly Mold Infections, Fauci Fifth Fallout, Liatris Spicata, Mental Health Screening Concerns, Toddler Ultra-Processed Foods, Prescribed Harm Remembrance, Homeopathy Protocols and MORE! https://robertscottbell.com/kennedy-obliterates-cnn-host-deadly-mold-infections-fauci-fifth-fallout-liatris-spicata-mental-health-screening-toddler-ultra-processed-foods-prescribed-harm-day-homeopathy-pellet-question-and/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Siyabonga Motha is joined by Dr Nhlamulo Hlungwane, a Family Doctor and Clinical Director of the Myclinic and Dr Mandy Mpatlanyane is a medical doctor to unpack the essential yearly screenings every woman needs, why they are so important, and how to make the most of your annual health check. Tags: 702, Aubrey Masango show, Aubrey Masngo, Bra Aubrey, Siyabonga Motha, Medical Matters, Dr Nhlamulo Hlungwane, Dr Mandy Mpatlanyane, Health screenings, Annual health check, Menopause, Pap smear, Mammogram The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Today, I am delighted to connect with Dr. Elisa Port, a talented breast surgeon with a passion for helping women better understand breast cancer, breast health, and the science behind screening, diagnosis, and treatment. She's the chief of breast surgery for Mount Sinai Health System in New York, a professor of surgery at Mount Sinai's Icahn School of Medicine, and the author of The Breast Advice. In our conversation, we explore breast cancer risk factors, various screening mechanisms and their impact on dense breasts, and the role of diagnosis and pathology, including DCIS. We also discuss menopause symptom management, anti-hormone and targeted treatments, immunotherapy, de-escalation, and why a personalized approach to breast cancer treatment is so important.  Stay tuned for a truly informative conversation with Dr. Port. With her infectious optimism, she has a wonderful way of translating the science and the research in her book, making it accessible and putting the statistics into context so the information feels far less scary than it otherwise might. IN THIS EPISODE, YOU WILL LEARN: How 90% of women diagnosed with breast cancer have no family cancer history How body weight and alcohol can influence breast cancer risk Why Dr. Port recommends annual mammograms beginning at age 40 for most women Dr. Port may disagree with recommendations against breast self-exams Why women with dense breasts may benefit from supplemental ultrasound or MRI in addition to mammography Unvalidated breast screening tests may lead to false positives, unnecessary testing, procedures, anxiety, and expense. What DCIS is, and how it influences treatment decisions Why an individualized approach is essential when using SERMs, SERDs, and aromatase inhibitors How Oncotype testing helps to identify women who may safely avoid chemotherapy Bio: Dr Elisa Port Dr. Elisa Port, MD, is chief of breast surgery at Mount Sinai Health System, which encompasses seven different breast centers. Her team performs over a thousand breast surgical procedures each year. She is also the director of the Dubin Breast Center, a state-of-the-art breast center in Manhattan that opened in April 2011. She personally consults with thousands of patients and performs hundreds of operations each year. Dr. Port is a trusted voice in the media and a sought-after speaker. She has been featured in The New York Times, NPR, CBS, Today, Mornings with Maria, and Pix11. In addition to her media presence, Dr. Port regularly speaks at public events and is invited to present at conferences and panels across the country. She lives in Manhattan with her husband and two dogs. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. Elisa Port On her website On her personal Instagram  Breast Advice MD on Instagram The Breast Advice Substack

Young mob were treated to a special surprise at the Garma Festival when Bluey made an appearance.

Diese Folge entstand in bezahlter Werbepartnerschaft mit SCARPA.Marion Essletzbichler ist Diätologin, Fitnesstrainerin und Gründerin von Klartext Essen. Nach 12 Jahren in der Onkologie-Reha hat sie sich 2026 selbstständig gemacht. Ihre Schwerpunkte: Sporternährung, RED-S, Körperbild, Frauengesundheit, Menopause, Hashimoto und Darmgesundheit.In diesem Gespräch erzählt Marion offen von ihrer eigenen Geschichte: Jahrelang unerkanntes RED-S (Relative Energy Deficiency in Sport) – trotz völlig normalem Körpergewicht."Ach, fuck, ich hab RED-S." – so beschreibt Marion den Moment, als sie Jahre nach ihrem Studienabschluss endlich verstand, was mit ihr los war.Wir sprechen darüber, warum gerade ambitionierte Hobbysportler:innen gefährdet sind, was der Körper tut, wenn die Energie knapp wird, und warum Genetik akzeptiert werden sollte, statt gegen sie anzukämpfen.Nicht die Zahl auf der Waage entscheidet über Gesundheit, sondern wie gut wir lernen, unseren eigenen Körper zu verstehen und zu versorgen.Was mich besonders bewegt hat: Marions Erfahrung aus 12 Jahren Onkologie-Reha – dass das Thema Körperbild und Schlank-sein-Müssen selbst bei einer lebensbedrohlichen Erkrankung bei vielen Menschen nicht verschwindet.Insights aus dem Gespräch:RED-S kann auch bei völlig normalem Körpergewicht auftreten – Schlankheit ist kein AusschlusskriteriumDer Körper priorisiert bei Energiemangel die Bewegung vor der Regeneration – Ermüdungsbrüche sind eine mögliche FolgeGenetik setzt reale Grenzen: "Wenn man ein Schäferhund ist, kann man kein Windhund sein." – dagegen anzukämpfen kostet unverhältnismäßig viel EnergieVerhaltensänderung gelingt eher über sichtbare Umfeldgestaltung als über reine WillenskraftAuch nach schweren Erkrankungen bleibt der Wunsch nach Schlankheit bei vielen bestehenDanke an Marion für die Offenheit.Mehr zu Marion: https://klartext-essen.me/Instagram: https://www.instagram.com/klartext.essen/Die Studie, über die wir sprechen: Hill et al., PLOS ONE 2026 – Screening for eating disorders and low energy availability in female trail runners: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0348896

This week in the Screening Room we’re talking about delayed honeymoons, tourist traps, murder plots, Marilyn Monroe’s first top billing, and the 1953 Henry Hathaway film ‘Niagara.’ Plus we make a mixtape inspired by the film with songs by Big Star, The Hollies, L7, and more. Become an All Access member and get ad-free listening by visiting disgracelandpod.com.See omnystudio.com/listener for privacy information.

There's been a lot of opposition to FIFA's plans to sell stakes in its competitions to private investors. UEFA, the governing body of football in Europe, have said they would boycott Fifa events if the plans go ahead. The Asian Football Confederation and Concacaf, which governs football in North and Central America, have also opposed the plans. BBC sports correspondent Patrick Gearey explains how this might affect women's football.A new study is investigating why autistic women are less likely to attend cervical screening. Many report pain, anxiety, sensory sensitivities and feeling dismissed during smear tests. Willow Holloway, who is autistic, joins Kylie Pentelow to describe her experience. Researcher Dr Aimee Grant, explains the barriers autistic women face, and why alternatives, like at-home HPV testing, could help improve access to life-saving screening. Do you remember your first kiss? Or perhaps your worst kiss? And what was your last kiss - a smacker, a snog, a pash - or rather a quick peck on the cheek? Maybe just an air kiss? Or perhaps you would rather keep your lips to yourself - and wish others would too. Professor Katie Barclay, a historian of emotions based at Macquarie University in Sydney, has taken a deep dive into a thousand years' worth of kisses for her new book The Kiss: A History of Passion & Power. She joins Kylie to explain why our ancestors had a kiss for almost every occasion but kissing is now in decline.In the 1990s the work of the young British playwright Sarah Kane caused controversy with its groundbreaking, unflinching portrayal of violence on stage. Almost 30 years after it was first performed, a revival of Kane's play Cleansed has opened at The Almeida, directed by the theatre's outgoing, Olivier award-winning Associate Director, Rebecca Frecknall. Now accompanied by content warnings, a self-care guide and a decompression space, how might today's audiences approach this confrontational work - and how does it feel to perform it? Kylie discusses with the director Rebecca Frecknall and actor Pearl Chanda, who plays Grace in this production.The UK's only all-women chess team has been crowned champions of the second division of the national league, winning them a historic promotion to the top tier. It is the first time an all-female team has reached the top division in the 33 years of the UK's national league and a big achievement by the She Plays To Win Lionesses, but because of league rules they may have to lose their all-women status, and include a man in the team to be allowed to play in Division 1. Kylie discusses the issue with Anusha Subramanian and Alisha Vyas - two members of the winning team.Presented by Kylie Pentelow Producer: Louise Corley

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about addressing medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to medical trauma in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 421: Medical Trauma in Oncology Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse ONS Voice articles: Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD [post-traumatic stress disorder] Past Trauma Lowers Hope, QOL, and Coping Ability During Cancer Managing Cancer-Related PTSD Starts With Acknowledgement Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress Clinical Journal of Oncology Nursing articles: How Can a Trauma-Informed Care Approach Be Applied to Patients With Gynecologic Cancer? Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS course: Psychosocial Dimensions of Cancer Care™ ONS Huddle Card: Coping Screening tools Clinician-Administered PTSD Scale for DSM-5 [Diagnostic and Statistical Manual of Mental Disorders, 5th edition] (CAPS-5) Hospital Anxiety and Depression Scale Primary Care PTSD Screen for DSM-5 PTSD Checklist for DSM-5 Trauma Screening Questionnaire International Society for Traumatic Stress Studies: Free Resources PESI Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "For many people who have been traumatized, if they can avoid it, they will. They may not avoid the annual evaluation that is so hugely consequential—they might not avoid that. But they may well avoid a routine visit for a checkup to their oncologist. They very well may avoid a visit with a psychologist who is wanting them to talk about hard things. They may avoid visiting a friend in the hospital because it reminds them of really upsetting things. So, this issue of adherence and compliance is a really big problem." TS 3:19 "Screening tools for things like PTSD can be very useful. They're quite practical, and they're appropriate to use. I really like something called the Post-Traumatic Stress Disorder Checklist. ... Using it is going to be very straightforward. You're going to want to map it onto a 30-day window, and you're going to employ it with patients. It's a 20-item self-report. It assesses 20 DSM-5 symptoms of PTSD. It's not diagnostic, but if people score in this range of 30, 31, 33, we typically are going to believe that that is very suggestive of significant PTSD." TS 9:17 "One of the things we should be doing all the time is modeling and attempting to normalize this idea of being open about mental health difficulties. When I say modeling, this is a complicated issue. ... I'm very open talking about my own battles with mental health. And in some ways, that invites my patients to do the same. I don't recommend necessarily that a nurse says, 'Oh, by the way, I have PTSD. I'm going to tell you about mine. I want you to tell me about yours.' That's a boundary issue. But I think it does behoove us as clinicians to create a culture as much as we're able, where we can talk about mental health difficulties in a matter-of-fact way, acknowledging that mental health is health. These tools, to me, go a long way in that direction." TS 13:41 "The survivorship process is ongoing. I think a nurse can assist a patient in so many ways longitudinally over time. ... One of those ways is to continue checking on mental health outcomes in patients. Continuing to check on mental health outcomes, continuing to explore them, and continuing to invite patients to talk about things that other people might not be asking about. It's easy for family members to assume, 'Hey, you know, you're cancer free now. You look fine, so you must be fine.' It's very possible that the patients we're talking about are not fine. They're far from fine. For that oncology nurse at a follow-up clinic or in an oncology setting to talk about this, continuing to affirm that it would be okay for patients to struggle, continuing to put this issue on a front burner—I think that's really important." TS 21:17 "I'm aware of nurse-led support groups where nurses can talk very freely about their own challenges, in a safe space. ... Working to build cultures in the context of the intensive care unit, let's say, where we have a lot of patients with cancer that prioritize well-being nurse driven programs. ...  The bottom line is if there is a warning light that is blinking, nurses need to attend to that. And in attending to it, they're going to be more present for their patient. They're going to be better able to support their patient. They're going to be better able to support each other. And I think often, in the culture of nursing and psychology, too, people just put their head down, their shoulder down, and they just plow through in ways that are really counter to their mental health." TS 29:56 "The truth is medical trauma can be well-managed. It's not simple. It's not always intuitive. There are all sorts of caveats with regard to this, but the truth is people with medical trauma can live really rich and meaningful lives. ... So, the default setting, I think, should be not one of pessimism. It should be that people with medical trauma can and do get better. If you are a patient with medical trauma and you are in my purview, until proven differently, I'm going to assume that you can get better too." TS 36:28

When your AC fails in a heatwave, you don't want a busy signal; you need a solution. Netic founder and CEO Melisa Tokmak joins host Elad Gil to explain how Netic's autonomous AI platform acts as an intermediary between companies and customers, deploying agents to instantly handle essential services, from emergency home repairs to hospitality to pet care. Melisa describes the complexity of these real-world workloads, which have traditionally relied on large human support teams, and how over 70% of Netic's customers interact first with AI. She also talks about the reasoning behind building a scalable product company rather than an AI roll-up, why she believes robotics will not catch up in these industries in the near future, why she doesn't view large frontier labs as competitive threats, and how private equity's playbook has shifted toward measurable ROI in the AI-era. Plus, why Melisa is optimistic about the impact AI will have on education. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @netic_AI | @melisatokmak Chapters: 00:00 – Melisa Tokmak Introduction 00:32 – What Netic Builds 03:53 – Automating Workflows for Essential Services 06:26 – Building a Service vs. AI Roll-Up 10:38 – AI for the Real World Timeline 12:56 – Can Big Labs Compete? 15:35 – Modern Founder Mindset 19:09 – Screening for Agency 22:25 – Five Year Vision 23:53 – Selling to Slow Industries 27:23 – How Private Equity Approached AI 31:14 – What Excites Melisa About the Future of AI 34:27 – Conclusion

Shira Boehler's family is full of doctors, and every one of them told her not to get the full-body MRI. She canceled the appointment repeatedly herself, until her husband rebooked it one time too many and she finally went.The scan found a 3.8 centimeter mass in her right lung and labeled it a minor finding, with a note to correlate with symptoms. She had none. She was running six miles a day, the picture of health, and had never smoked. A follow-up CT months later showed the mass had grown, and on the Monday she walked into a pulmonary specialist's office she was told she had an invasive adenocarcinoma. She told him it was probably an EMR error. One week later, surgeons removed half her right lung to treat her cancer.Samira Daswani, host of Patient from Hell and founder of Manta Cares, welcomes lung cancer survivor and bestselling author Shira Boehler for an eye-opening conversation on the part that comes after the story, which is why almost nobody in Shira's position gets caught this early. Screening guidelines currently cover people over 50 with a twenty-pack-per-year smoking history, and fewer than one in five of them actually get scanned, in part because the criteria require disclosing something patients are ashamed of. Shira has been working the problem from both ends since her treatment, negotiating cash prices at imaging centers down to a fraction of what she paid and funding new scans for people who can't cover them through the nonprofit organization she founded, Cancer Doesn't Care.In this episode, Samira and Shira discuss:Why lung cancer is often diagnosed too lateThe importance of early detection and low-dose CT screeningHow people who have never smoked can still develop lung cancerThe stigma surrounding lung cancer diagnosisCurrent lung cancer screening guidelinesInsurance coverage, healthcare access, policy reformHow artificial intelligence may improve cancer screeningWhy patient advocacy is becoming increasingly important in modern healthcareChapters00:00 Introduction01:00 The Full-Body Scan That Changed Everything03:32 Diagnosed With Lung Cancer Despite Having No Symptoms05:30 Access, Privilege & Why Early Detection Isn't Equal07:10 Building the Cancer Doesn't Care Foundation09:21 Why Lung Cancer Screening Needs to Change10:19 Breaking the Stigma Around Lung Cancer12:26 Who Actually Qualifies for Screening?14:23 Changing Public Perception Through Advocacy16:20 Why Patients Must Advocate for Themselves17:15 AI, False Positives & the Future of Cancer Screening20:27 Why Lung Cancer Is Often Diagnosed Too Late21:17 Stage 1 vs. Stage 4 Survival Rates23:25 Shira's Advice for Anyone Considering Lung Cancer ScreeningShira Kupperman Boehler is a finance professional, health advocate, bestselling author, and lung cancer survivor. Shira holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. Alongside her husband Adam, she has spent her career building and scaling multibillion-dollar healthcare businesses, developing deep relationships across health systems, payers, and policymakers.After being unexpectedly diagnosed with Stage 1B lung adenocarcinoma despite never smoking and having no symptoms, Shira founded Cancer Doesn't Care, a nonprofit dedicated to expanding access to life-saving lung cancer screening and reducing financial barriers to early detection. She is also the author of the bestselling memoir One Scan Saved My Life, with proceeds supporting patient screening initiatives.

Rena Comer of CCCW returns to Talk City Greensboro to share how the organization, Caribbean Crusade for Christ World-wide's annual Back-to-School program on Saturday, August 8th. Bring your child for a free health screening, Backpack and Raffle Giveaways. Everything is on a first com first serve basis. So, get there early to have your student's blood pressure, blood sugar, plus hearing and vision screenings. Community vendors will be on hand as well. Doors open at 10am and the program runs until 2pm. Watch and listen to learn details.

SpaceX's Starship megarocket makes the 'softest splashdown' ever (05:09)  Pentagon launches testosterone screening program for troops (15:46) Sailors could live in RVs or houseboats as Navy overhauls barracks (27:06) Unheralded History: Bow and Arrow use in the Vietnam War (36:26) https://lateforchangeover.com/ #lateforchangeover #veteranvoices #militaryeverything #militarypodcast #spaceforce #airforce #army #navy #marines #coastguard #militaryhistory #militaryhumor

In this episode of The Lead, host Tina Baykaner, MD, MPH, is joined by Christopher Kowalewski, MD, and Marco Perez, MD, to discuss the journal article, Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Together, they review findings from this secondary analysis of the LOOP Study and explore the relationship between genetic risk and atrial fibrillation screening. Learning Objectives Review the key findings from the secondary analysis of the randomized LOOP Study examining atrial fibrillation screening according to genetic risk. Discuss the relationship between genetic risk and atrial fibrillation screening as evaluated in the study. Explore the potential implications of incorporating genetic risk into atrial fibrillation screening strategies.   Host: Tina Baykaner, MD, MPH Guests: Christopher Kowalewski, MD and Marco Perez, MD   Disclosures: T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   C. Kowalewski No relevant disclosures   M. Perez Ownership/Partnership/Principal: QALY Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik Research: Apple, Inc. Other/Stock Options Privately Held

Hollywood is not trying to stop a monopoly by blocking the Paramount Skydance merger with Warner Bros. It's trying to protect one.If a monopoly means near-complete control over what gets made, promoted, and rewarded, then much of Hollywood and the cultural institutions around it operate under the ideological consensus of the Left and the Democratic Party. Why do the Obamas have a long-running production deal at Netflix? Why do the Emmys consistently elevate late-night hosts whose politics align with that consensus? Jimmy Kimmel, John Oliver, Stephen Colbert, Jon Stewart? Do you think they'd ever nominate Greg Gutfeld, whose show often tops them all in ratings? If that isn't an ideological monopoly, I don't know what is. Why did major awards shows stay silent on Charlie Kirk? Why did so many artists cancel Kennedy Center appearances after its Trump-era changes, and why did multiple acts drop out of America 250 events?David Ellison and Paramount Skydance are attempting something brave and unprecedented: an outside challenge to that consensus. Their roughly $110 billion bid for Warner Bros. Discovery would give them control of a major studio, HBO/Max, CNN, and a large portfolio of cable and streaming assets. While there has been some resistance to the biggest mergers in recent history, we've never seen anything like #blockthemerger. Meet the new resistance, same as the old resistance. 12 state attorneys general, including California, have sued to block the deal. The Writers Guild of America has filed its own antitrust lawsuit. SAG-AFTRA has publicly opposed the merger, though it has not joined the litigation. Opposition also includes the Future Film Coalition (which leads the #BlockTheMerger campaign), Democracy Defenders Fund, Committee for the First Amendment, Free Press, the International Documentary Association, and the American Economic Liberties Project, among others. More than 5,600 industry figures have signed an open letter against the deal, including Mark Ruffalo, Jane Fonda, Javier Bardem, Elliot Page, Emma Thompson, Ben Stiller, and Cynthia Nixon.Paramount Skydance has, for now, delayed closing. Can they hold the line under this unprecedented pressure campaign? Hope springs eternal. But you won't read about that point of view in any of the trades. They're a monopoly, too. Most of them are owned by the same entity, Penske Eldridge. Just today, it was announced that the Hollywood Foreign Press, the former owners of the Golden Globes, are suing Jay Penske for $150 million. They are claiming Penske orchestrated their downfall so he could buy the Golden Globes. Jay Penske already owns Deadline, The Hollywood Reporter, Variety, Indiewire, Gold Derby predicting site, Rolling Stone, a virtual monopoly on the awards race from soup to nuts. Gold Derby shapes the nominees, the trades take ads from the studios and the Golden Globes hand out the awards. But wouldn't you know, when Rebecca Keegan wrote a hit piece on me, she did so in the Hollywood Reporter, owned by Penske Eldridge. I was a vocal and prominent critic of Penske's growing monopolistic power on the awards race and one of the few willing to speak out. With one hit piece, the Penske company took out both a competitor for ad money and a pesky nuisance for the brand. That is what you call a monopoly. A Climate of Fear and A Culture of SilenceI found out firsthand how monopolies work in Hollywood when I was canceled in 2024. The day a Hollywood Reporter story labeled me a “MAGA darling,” one studio pulled its ads from my site that day. The last thing they wanted was to be associated with an accused and condemned witch.It was shocking how many of them fell in line in robotic fashion, gripped with fear. The response was swift and uniform. Every writer on my site left to protect their reputations. Friends of fifteen years ended the friendship. My Oscars ticket was revoked. Jane Fonda's Women's Media Center fired me from their annual Oscars report. Screening and party invitations dried up. I was benched on Gold Derby.Worst of all, the lucrative studio ad buys for the Oscars and Emmys vanished. As it all collapsed, I remembered in 2012, an advertising strategist telling me I could be making far more money if I sold the site better. “You have no baggage to speak of,” she'd said.That was true then. I was one of the few independent Oscar sites left, and still am, known around town for being honest to a fault. I stayed independent even as the ad money made life more comfortable for me and my daughter than it had ever been.There was never any question why my career ended in Hollywood: I had been outed as a Trump voter. I was on the wrong side of Hollywood's progressive orthodoxy, and that meant I was finished.How it started…I started Oscarwatch.com as a single mom with a one-year-old baby living in a studio guest house in Van Nuys, California, in 1999. I was an early web pioneer with a 1200-baud modem and a really good idea. I was already catching the attention of publicists and rocking the boat, as all of us amateurs did back then. We were moving fast and breaking things. Traditional media was not ready. The studios weren't either. They were used to having a monopoly on Oscar FYC ads in Variety and the Hollywood Reporter, their bread and butter. Until the blogs came along.By 2006, I was starting to make money because my little site had birthed a big bang of other Oscar sites, and by then even the New York Times had an Oscar blogger, the late great David Carr, who called himself the Carpetbagger.David Carr became a mentor of sorts and encouraged me to sell ads for myself, rather than piggyback off bigger sites. I was working three jobs by then: as a horoscope writer under a pseudonym (Laura Wilde), a janitor working my dad's routes because he was a good guy and knew I needed the money, and a freelance film critic.Right around then, the Academy of Motion Picture Arts and Sciences sued me for trademark infringement, and my site was renamed AwardsDaily.com. Now I was cleared to start making real money.David Carr was horrified that I was working as a janitor while the trades were raking in millions on Oscar ads and encouraged me to start sending out RFPs. But I didn't have to, because before long the studios were sending them to me. My site became so influential that I never really had to pitch to them. They all wanted real estate on my site. Who could ever have imagined that? Certainly not me, someone who got online in 1994 back when no one thought you could make money on the internet.One of the first studios that bought ads was Fox Searchlight, an awards subsidiary of Fox. I called it Big Fox and Little Fox, and both advertised on my site. When I got my first $15,000 just to run ads, I was stunned. That was more money than I had ever seen on a check. I was just kind of faking it, pretending I knew what I was doing, but I really didn't.Of course, it was also about promoting films the studio wanted to place in the Oscar race, and that's still what it's about. It's not exactly pay-to-play, but most of the bloggers making money in the Oscar game are grateful and help keep the advertisers' movies prominent. I did too.I barely noticed in 2019 when Disney bought Fox for $71 billion. The Writers Guild objected to the merger, just as they have to the Paramount Skydance merger with Warner Bros., but there was nowhere near the same amount of public outcry.Trump praised the Disney/Fox merger after having attempted to stop the 2018 merger of AT&T and Time Warner, leading to a trial, but the judge ruled against the Trump administration, and the deal went through. Again, no major public outcry.At some point after 2020, I'd noticed that Disney had stopped advertising on my site. I wrote it off as their shying away from my comments on “gender affirming care” for kids. I'll never know exactly why, but all I do know is that once the merger went through, Fox and Fox Searchlight also stopped advertising. The Paramount/Skydance merger with Warner Bros. is significantly higher and covers more territory than any of the major corporate mergers we've seen as Hollywood reshuffles the deck amid the shift to streaming. Warner Bros. was selling. The only question was whether Netflix or Paramount Skydance would buy it. Both deals would have had the blessing of the Trump administration.But because it's David Ellison and the team that bought CBS, and because Trump is an ally, the Democrats and the Left have turned #BlockTheMerger into another No Kings protest or battle for the “resistance.”After the story about me broke in the Hollywood Reporter, Netflix also stopped advertising. No other studio except Focus Features, an adjunct of Universal, had the courage to run ads on my site. I was now officially blacklisted. Emails to the various studio reps went unanswered.This past year, Paramount bought a modest ad package on my site for the Emmys to celebrate the success of Landman and The Madison. I felt lucky to get it, and it was a sign, at least to me, that Paramount, like Focus Features, was brave enough to take a chance on someone deemed too toxic by the industry.Landman, Taylor Sheridan's Billy Bob Thornton drama, had become one of Paramount+'s biggest hits: its first season averaged 15.8 million viewers in Nielsen's cross-platform ratings and ranked among the top 10 series of the 2024-25 season. Season 2 opened to a Paramount+ record 9.2 million views in its first few days and continued to dominate the streaming charts, at one point leading all multiplatform viewing with more than 14 million. The Madison, starring Michelle Pfeiffer, launched as Sheridan's biggest series debut yet, drawing 8 million views in its first 10 days.But unfortunately, #blockthemerger had bled into the awards ecosystem, which remains a closed loop. Sure enough, when the Emmy nominations arrived, the Paramount shows were completely blanked—even Billy Bob Thornton in Landman and Michelle Pfeiffer in The Madison. Kathy Bates was similarly overlooked for Matlock.If Gold Derby shapes the Emmy nominations, and they do, they have to similarly play ball by blacklisting all Paramount Plus's most popular shows, proving to American audiences that the industry does not care about what they want or what they watch. Sheridan has transformed much of the television landscape, thanks to Paramount Plus. If Paramount buys Warner Bros., they won't be creating a monopoly but breaking one up. The Death RattleI know I should walk away from this industry and give up the site that took me 26 years to build. But I just can't do that. I can't let them win. Now that I've walked in the shoes of the other half of the country, I can clearly see why Hollywood's empire is collapsing. If ratings and box office don't matter, neither do audiences. None of this is about artistic freedom or making better movies or television shows. This is the Left flexing its muscle in an attempt to keep all of Hollywood to itself, to push its ideology on the people, to convert them, to indoctrinate them, to “correct them,” everything but entertaining them. Most of all, though, it is about one man: Donald Trump and their failure to stop him, destroy him, kill him, or exile him and his supporters. This is one of the most exciting times to be living through in American history, but you'd never know it by the movies and TV shows Hollywood pumps out. Their monoculture, their one-sided point of view, has choked the life out of Hollywood. If they could make fun of themselves, if they could humanize their fellow Americans, they might be able to tell stories that resonate with everyone. Maybe, just maybe, they would breathe new life into a decaying organism.But they can't risk it. Like the Democrats who don't trust the people with elections, Hollywood doesn't trust them with the culture.Elon Musk spent $44 billion to take Twitter out of the hands of its previous gatekeepers. Ellison is now trying to pry open a crack in the thick shell of Hollywood's product and return more of it to market forces and all of those people Hollywood left behind. // This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sashastone.com/subscribe

Apply for Personal Training with us: https://link.elite360.io/widget/form/T5CK4VnbyZVEkSt3CzF3Get HUGE Savings on clean natural supplements from Legion!https://legionathletics.com/Use the code "Disneyfit" at checkout for a BOGO 50% off on your first purchase and 10% Cash back every time after that!Disney Themed Fitness Group-https://www.skool.com/magical-transformations/aboutInstagram-https://www.instagram.com/themagicalfitcoach/https://www.instagram.com/dinksndisney/

5 Midlife Screening Tests That Give You a well deserved Unfair AdvantageWhere to get a DEXA scanWhere to get a Continuous Glucose Monitor  I've used Ageless Rx and had a good experienceWhere to get a VO2 max testFeeling overwhelmed by “all the guidelines”? In this episode, I narrow it down to five screening tests that are actually worth your time in midlife.  Especially if you want to feel strong, independent, and fully alive in your 70s and beyond. We start with the biggest threat to long-term health (metabolic dysfunction) and why tracking your glucose (ideally with a continuous glucose monitor) can change everything. Then we cover the DEXA scan for bone density, muscle, and visceral fat, plus the VO2 max test as the #1 predictor tied to all-cause mortality. We also talk smarter cardiovascular risk screening (beyond basic cholesterol, plus blood pressure) and cancer screenings that still matter: colorectal, breast, cervical, and skin. The theme: don't aim for normal.  Aim for optimal.00:00 Why Screenings Matter00:32 Show Intro And Mindset03:06 What Counts As Screening04:42 Aim For Optimal07:39 Test One Glucose Tracking09:41 Test Two DEXA Scan11:59 Test Three VO2 Max15:21 Test Four Heart Risk Labs20:16 Test Five Cancer Screening23:30 Wrap Up And Next WeekAre you ready to give your cells their best chance to not have to stop living before they die by allowing them access to physiologic levels of hormones, but aren't sure how to even get started?  Join the waitlist for my new beta program here and help me figure out how best to help wonderful women like you get the hormone care they deserve!Join the Waitlist HereCome visit me: www.healthcouragecollective.comemail me: healthcouragecollective@gmail.com

** Want more? Become a part of my community! Sign up for Zibby's Highlights, which includes a free weekly newsletter, event livestreams, most anticipated book lists, personal essays, and a new essay platform with stories from all of you about what chapters you're in (inspired by my upcoming book Between Chapters: How I Started Over, Took Some Chances, and Found the Plot, 9/22/26). And follow me on Instagram @zibbyowens. But really, keep listening here. If you love my show, please tell a friend! Hosted on Acast. See acast.com/privacy for more information.

Screening Familiar para Cardiomiopatia Arritmogênica by Cardiopapers

Picture this: working two jobs, sleeping during your breaks, and still showing up every single day because you've already decided what your life looks like on the other side! That's exactly how today's guest turned a two-year grind into his very first real estate deal—and if he could unlock his dream life with just one property, you can too! Welcome back to Real Estate Rookie! Today we're joined by Elijah Ray, who spent two years working 100 hours per week between two jobs, with one goal in mind: to live his dream life. Elijah sat down every week to look at his goals and work backward from them, until he had enough saved to buy his first property at just 26 years old! In this episode, Elijah shares how house hacking one property gave him the freedom to finally quit his job, how he funded his first rental unit, and how his first (and only) property unlocked the life he's always dreamed of! If you're grinding through a job you're trying to escape and telling yourself it's not possible yet, this episode is proof it just takes one clear goal and one deal to change everything. Hit play to hear exactly how he did it! In This Episode We Cover How Elijah set his goals and bought his first home (even after a two-year struggle!) Managing evictions as a rookie landlord and the lessons that came with it  Screening red flags Elijah wishes he'd caught on his first rental property  Why less rentals meant more freedom (you don't need a dozen units!) How to fund a renovation with credit cards, and whether it's worth it The 1% down payment loan that speeds up your buying timeline  And So Much More! Check out more resources from this show on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BiggerPockets.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠h⁠t⁠⁠tps://www.biggerpockets.com/blog/rookie-749. Interested in learning more about today's sponsors or becoming a BiggerPockets partner yourself? Email ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠advertise@biggerpockets.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.  Learn more about your ad choices. Visit megaphone.fm/adchoices

33-years ago, the family classic 'Free Willy' opened in theatres and became a hit leading to two sequels and a film still revered today. Star Jayne Atkinson will be doing an event at The Triplex in Great Barrington on July 29th at 7 pm for a talkback after a screening of the film.

How Making a Stroke Recovery Documentary Helped a Former One-Percenter Reclaim His Life Shayne DeMarce spent most of his adult life defined by physical strength. He rode Harleys through the Canadian Rockies in every season, ran a plumbing and heating business, and had recently begun prospecting with a one-percenter motorcycle club drawn there, he says, by the brotherhood at a time when his wife’s cancer diagnosis and a failing business were pulling the rest of his life apart. Then, on a low-speed group ride at under 20 kilometres an hour, his back wheel slid on loose gravel. To avoid landing on a fellow rider, he dove off his bike into a ditch and broke nine of his twelve ribs, his collarbone, and his scapula, punctured a lung, and tore his aorta. What nobody caught for another thirteen hours was that he’d also had a stroke. A Low-Speed Crash With High-Speed Consequences Shayne’s accident is a reminder that the danger in a fall isn’t always where it looks like it is. He walked away from the crash site convinced his injuries were broken bones, painful, but familiar territory for a man who’d spent a lifetime playing football, doing judo, and dirt biking. It wasn’t until he was in the truck heading to hospital, feeling suddenly and inexplicably worse, that anyone suspected something else was happening. By the time doctors in Edmonton confirmed it was a bilateral carotid artery dissection that had cut off blood flow to his brain, the left side of his body was already gone. He spent five months in hospital and ICU, then seven more in inpatient rehab. Non-weight-bearing for most of that time, he had to relearn how to exist in a body that no longer matched the identity he’d spent decades building. Losing the Body He Built His Identity On “I was a physical guy,” Shayne said. “My job was physical, everything about me was physical. So it wasn’t just my identity; it really was who I was.” For a man whose sense of manhood was tied to strength, work capacity, and being able to hold his own, losing the use of half his body wasn’t just a medical setback. It was, in his words, “very humbling.” The turning point came from an unexpected source: a blunt question from the principal at his rehab facility’s education centre. When Shayne told her his only goal was getting his body back, she asked him plainly, “So what if you don’t get your body back?” It’s a question that stroke survivors and their families rarely get asked directly, and it’s often the one that needs asking. Shayne describes it as heartbreaking in the moment, and something he’s since come to be grateful for. Why He Turned to a Camera Instead of a Gym That question pushed Shayne toward a skill he’d never have considered before his stroke: typing, then editing, then filmmaking. He describes teaching himself to type as doing more for his affected hand than any of his occupational therapy, and it opened a door to something bigger. Once home, he noticed a gap: plenty of content from doctors and news stations about stroke, but very little from survivors themselves, talking honestly about what recovery actually looks like. So he started the UpStroke Podcast. Then, within days of getting home from inpatient rehab, he set himself an ambitious goal: make a full-length stroke recovery documentary about his own experience, and finish it within six months. No film background, no crew, no guaranteed audience just early mornings, self-taught editing, and a refusal to let pride keep him from trying something that scared him. Making a Stroke Recovery Documentary From the Ground Up The finished film runs 55 minutes and represents hundreds of hours of work planning, scripting, filming, and re-filming after the inevitable rookie mistakes (forgotten microphones, unrecorded interviews, background noise nobody caught until the edit). Shayne interviewed his own kids and friends for the film, describing the process as “ripping the same band-aid off fifty times a day for six months straight.” What makes a stroke recovery documentary like this different from a polished studio production is exactly what makes it valuable: it was built by someone still living the recovery it documents, using the same self-taught persistence he’d once applied to fixing pipes and riding through winter. Screening the Film for the People Who Understand It Most The most meaningful moment of the entire project, Shayne says, wasn’t a premiere or a review; it was screening the documentary at the rehab facility where he’d been an inpatient, for a room that was roughly 80% stroke survivors and staff. He remembers patients in that same gymnasium who never had a single visitor in six months, and he now sees his film and podcast as a way to reach exactly those people: the ones running out of hope in a system that doesn’t always have room to give them much of it. A New Club Shayne no longer rides with the one-percenter club he’d started prospecting with before his accident. He describes his community now as “a bunch of stroked out strokers,” the friends, fellow survivors, and families he’s met through the podcast and the film. It’s a different kind of brotherhood than the one he set out to find, but by his own account, it’s the one that’s carried him. His documentary is now available free on YouTube, so that as many stroke survivors, caregivers, and healthcare professionals as possible can watch it. If Shayne’s story resonates with where you are in your own recovery, Bill’s book, The Unexpected Way That A Stroke Became The Best Thing That Happened, walks through ten tools for recovery and personal transformation built from these same kinds of conversations: recoveryafterstroke.com/book. If this show has helped you, you can support it at patreon.com/recoveryafterstroke. Footer Disclaimer: This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. The transcript will be available soon… The post The One-Percenter Biker Who Turned His Stroke Into a Documentary appeared first on Recovery After Stroke.

In this episode of Healthcare Beans, James speaks with Ryan Polselli, MD, founder and CEO of MammoLink, about why breast cancer screening remains underused despite decades of awareness, established clinical guidance, and broad insurance coverage. Ryan argues that the core problem is not simply awareness. Screening often conflicts with work, family responsibilities, appointment availability, financial uncertainty, and the natural tendency to postpone preventive care when no symptoms are present. He explains how MammoLink brings mammography and ultrasound directly to workplaces, schools, government sites, and rural communities through patient-centered mobile imaging units. The conversation also explores price transparency, payer quality incentives, direct-pay demand, rural health infrastructure, employer-sponsored screening, nationwide expansion, and the role of data and emerging technologies in the future of breast cancer detection. Episode Timeline 00:00 — Introduction to Ryan Polselli and MammoLinkRyan introduces his background as a board-certified radiologist and breast-imaging specialist and describes his focus on improving access to breast cancer screening. 01:02 — The breast cancer screening paradoxDespite widespread awareness and strong evidence supporting screening, many women still do not receive regular mammograms. Ryan explains why awareness alone has not produced sufficient action. 03:35 — Where the screening process breaks downThe discussion examines the balance between personal responsibility and system responsibility, including the burdens created by work, family obligations, and limited appointment availability. 04:56 — Designing preventive care around human behaviorRyan contrasts urgent medical care with preventive screening. When patients feel healthy, completing screening requires a proactive decision without the emotional urgency that drives emergency care. 06:06 — Making screening compatible with everyday lifeRyan argues that screening must be redesigned around how women actually live rather than requiring patients to navigate numerous scheduling and logistical barriers. 07:12 — Financial barriers and uncertaintyInsurance may cover a routine mammogram, but patients can still face uncertainty involving supplemental imaging, dense breast tissue, diagnostic follow-up, and unexpected bills. 09:23 — Delayed results and lost momentumLong waits for results can increase anxiety and weaken engagement. Ryan explains why faster feedback can restore patient control and encourage better screening habits. 10:39 — From patient experience to systems changeMammoLink began as an effort to improve the individual screening experience but evolved into a broader model connecting patient behavior, economics, employer interests, and payer incentives. 13:04 — How the mobile imaging model worksRyan describes mobile units containing mammography, ultrasound, changing areas, procedure rooms, and other features typically found in an outpatient imaging center. 13:55 — Bringing screening into workplaces and communitiesRecurring visits to schools, employers, municipalities, and government sites allow patients to receive screening where they already spend their time. 14:20 — Social reinforcement and screening adherenceCoworkers can encourage one another to participate, while returning to the same location each year can make regular screening easier to remember and complete. 16:09 — The economics of mobile mammographyMobile screening carries higher capital and operating costs than traditional outpatient imaging, but Ryan describes it as a high-cost, high-yield model capable of reaching populations that might otherwise remain unscreened. 17:00 — Legislative and payer tailwindsCoverage changes involving supplemental breast imaging, along with growing payer interest, may improve the economic viability of comprehensive mobile screening. 18:27 — Access is also about timeRyan emphasizes that patients can be disadvantaged by limited time and flexibility even when they are not financially disadvantaged. 19:54 — Incentives within traditional imaging pathwaysThe conversation considers how fee-for-service payment can encourage separate visits, while a mobile model has stronger operational reasons to complete as much of the episode as possible in one encounter. 21:02 — HEDIS measures and payer motivationRyan explains how quality measures and Medicare Advantage star ratings can create significant incentives for health plans to improve breast cancer screening rates. 22:27 — MammoLink's no-surprise-billing approachRyan describes the company's decision not to send patients an unexpected bill after the visit, even when that means accepting some lost revenue. 25:05 — Technology supporting payment verificationMammoLink is using automated insurance-verification technology to improve up-front accuracy while preserving its principle of no back-end patient billing. 25:30 — Can transparency increase competition?The discussion turns to whether better consumer awareness of price differences between hospitals, outpatient centers, and alternative providers can eventually place downward pressure on costs. 26:46 — Direct pay, privacy, and convenienceRyan discusses the growing number of patients who choose cash payment because they value privacy, simplicity, or freedom from insurance-related friction. 27:51 — Supporting patients after an abnormal findingMammoLink manages diagnostic evaluation up to the point of biopsy and is developing stronger relationships with breast surgeons and health systems to improve downstream handoffs. 29:55 — The rural breast-imaging access gapRyan describes rural communities where mammography may not be available locally and where patients can postpone evaluating a concerning symptom for long periods. 30:40 — Public-sector and community partnershipsMammoLink works with the Florida Department of Health, migrant health organizations, and other partners to bring screening into underserved areas. 31:52 — Rural transformation funding as infrastructure capitalRyan and James discuss whether public funding could cover the initial cost of mobile units while allowing the operating model to become sustainable without permanent subsidy. 33:13 — Expanding beyond FloridaRyan outlines a potential national growth strategy involving grants, outside investment, and targeted entry into cities or states with favorable conditions. 33:55 — Bootstrapping five mobile unitsRyan discusses building the company without outside venture funding and reflects on the effort required to create its existing mobile fleet. 34:22 — The future of patient-centered mobile screeningRyan distinguishes genuinely patient-centered mobile care from simply relocating a traditional service and argues that future expansion will depend on proving outcomes and financial value. 35:30 — Demonstrating employer return on investmentThe conversation explores using clinical, operational, employee, and geospatial data to help employers measure cancers detected, time saved, employee satisfaction, and potential avoided costs. 37:05 — Employers as a preventive-care access channelRyan predicts that employers could play a larger role in providing screening as they seek to strengthen benefits, workforce health, retention, and trust. 37:38 — AI and emerging breast-cancer detection toolsRyan discusses research involving AI, biological markers, RNA-based technologies, and other emerging tools that may complement mammography and genetic screening. 38:39 — No mission without marginThe episode closes with a reflection on why healthcare innovation must be economically sustainable to achieve lasting scale and impact. Godspeed.. James Note: Some statistics and estimates discussed in this episode were provided conversationally by the host or guest and may be approximate. They have not all been independently verified by Healthcare Beans. Listeners should consult current primary sources before relying on specific figures for medical, policy, or business decisions.

China will step up support for people with autism over the next five years, expanding early screening and intervention services for children. The country will also increase the availability of specialized education programs.

Juexiao Sherry Wang, C J Battey, Kyle Trettin, Ravi Patel, Anu Srinivasan, Janani Saikumar, Divya Kushnoor, Ben F Habermeyer, Sangita Ganesh, Nafei Xu, Nathaniel Friedrich, Summer Pierson, Helen Wan, Heather LaBreche, Genevieve M Gould, Dale Muzzey. Simultaneous Prenatal cfDNA Screening of Aneuploidy, Recessive Single-Gene Conditions, and Fetomaternal Blood Compatibility. Clinical Chemistry, Volume 72, Issue 6, June 2026, Pages 679–691. https://doi.org/10.1093/clinchem/hvag005

Idea: For movie theaters to show a movie in the morning specifically for senior citizens, including discounts and special accommodations. Also: special accommodations could include selling Werther's and prune juice as snacks, having large-text subtitles, having an intermission to explain the plot of the movie to those who have questions, having defibrillators on standby, etc.; some movies would star older actors and be in the recently popular mini-genre where the plot is "they're not too old to do some fun thing"; memories of old people giving us Werther's as kids, and how Sugar-Free Werther's don't cause cavities because (according to AI) the bacteria in your mouth can't ferment the sugar alcohols into tooth-enamel-destroying acid Nicole Gilbert (instagram.com/nicolegilbertcomedy facebook.com/nicole.gilbert.75) Juwan Tett (facebook.com/juwan.tett instagram.com/jahdawan instagram.com/newworldcomedynwc) Rob Bagley (facebook.com/ComicRobBagley instagram.com/comicrobbagley youtube.com/@robbagley) Tom Walma (https://creativitywasted.com/creativitywasted x.com/thomaswalma twitch.tv/gameymcfitness) This podcast is part of Planet Ant Podcasts (https://planetant.com) This podcast is powered by Pinecast.

Sunset Boulevard reopened to traffic overnight after LADWP crews finished repairs on a ruptured water pipe in West Hollywood. The Los Angeles County Sheriff’s Department is investigating anti-semitic graffiti that defaced a mural at a Pasadena Synagogue. A trip to a Sylmar graveyard screening a cult classic Ed Wood film tonight. Plus, more. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comSupport the show: https://laist.com

This week in the Screening Room we’re talking about manifestos, art movements, outsiders, would-be societies, and the 1996 film ‘I Shot Andy Warhol.’ Plus another Hypothetical Theoretical Metaphorical Potentially Possible Mixtape with songs by Swamp Dogg, Pet Shop Boys, Lou Reed, and more. Become an All Access member and get ad-free listening by visiting disgracelandpod.com. See omnystudio.com/listener for privacy information.

This episode we discuss the rebounding of movies in the theatre. The hype around 'The Odyssey' and the latest in politics.  To become an official Brooklynite join here: https://www.patreon.com/c/LE2B/posts

  In recognition of World Brain Day, Dr. Kelly Tremblay explores why brain health requires a whole-person approach. She explains how hearing, vision, nutrition, mobility, and social connection all play critical roles in cognitive health, and why addressing these factors early can reduce the risk of dementia, falls, and other age-related challenges. Kelly also introduces the World Health Organization's free Integrated Care of Older People (ICOPE) screening tools, which empower individuals and communities to monitor brain and overall health through easy-to-use, multilingual assessments.  Tune in to learn how proactive screening and integrated care can help extend not just lifespan, but healthspan, while supporting independence and quality of life. To learn more, join us at our AgingIN conference and discover what the World Health Organization and your peer communities are doing to make aging better: https://aginginnovationconference.org/program/longevity-summit/ More about ICOPE here: https://www.who.int/publications/i/item/9789240103726

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Johnny Jet, travel influencer, joins Bob Sirott to talk about O’Hare’s latest taxi times, who has the most flight cancellations, and what rights you have if your flight gets canceled. He also explains what you should do before and after you rent a car, why air fares are still high, and off-site TSA screenings.

The law requires hospitals to post no-weapons notices but does not require detectors. Some patients say physical screening would give them greater peace of mind.

Last week, the US Defence Secretary announced a new policy that will require US military personnel to undergo annual screening for testosterone deficiency, however some health experts have expressed concerns that this program could have negative effects. Claudia Hammond speaks with Gary Wittert, professor of medicine at Adelaide University and consultant endocrinologist at the Royal Adelaide Hospital, to understand more about testosterone and what hormone replacement therapy can do to the body. Many babies receive a vitamin K shot after birth to prevent internal bleeding, but recently more parents are declining this potentially life-saving treatment. Dr Matthew Fox, Professor of Epidemiology and Global Health at Boston University, joins Claudia to explain what is driving this trend, and the evidence behind the jab.Professor Rebecca Katz from Georgetown University in Washington DC and Director of the Health Security Operations Center has been monitoring disease spread and public health risks during the Men's Football World Cup, and joins Claudia to share what went well and what we have learned through this monitoring process.A microscopic parasite, cyclosporiasis, is causing a gastrointestinal outbreak in the United States – Matthew and Claudia discuss the possible sources and what is being done to combat it. And, how El Salvador eliminated trachoma – the world's leading infectious cause of blindness.Presenter: Claudia Hammond Producers: Jonathan Blackwell and Georgia Christie

Congenital cytomegalovirus is a common viral infection that passes from mother to fetus during pregnancy. It affects about one in 200 babies in the US.

Disclaimer: This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to your own physician before making decisions about cancer screening, testing, or treatment.TL;DR* A healthy 58-year-old gets a routine full-body scan, finds a “cancer” that would never have hurt him, and ends up with permanent incontinence from unnecessary treatment. This is more common than most people realize.* Dr. H. Gilbert Welch, a Dartmouth-trained cancer epidemiologist, spent 30 years documenting overdiagnosis — the discovery of cancers that meet the technical definition but would never have caused harm. His estimate: roughly 60% of PSA-detected prostate cancers and 25% of mammography-detected breast cancers fall into this category.* The “5-year survival rate” you hear cited as proof screening saves lives is often distorted by lead-time bias — finding a cancer earlier can make survival numbers look better without adding a single day to anyone's life.* Not all screening is suspect. Colonoscopy, low-dose CT for high-risk smokers, and cervical cancer screening (Pap/HPV) have strong randomized-trial evidence behind them.* The piece conventional screening misses: metabolic health. A 2026 Nature Communications study using machine learning on UK biobank data linked insulin resistance to increased risk across at least 12 cancer types — independent of body weight — and standard checkups rarely test for it.* Want a personalized look at your own metabolic terrain? Book a Metabolic Audit Call — link in show notes, spots limited weekly.The Test That Didn't Save His LifePicture a 58-year-old man. Healthy weight, active, doesn't smoke, feels completely fine. He goes in for a routine total-body scan — the kind now available at imaging centers with no doctor's referral required. Two hours later, a radiologist flags a small spot on his prostate.Six months, two biopsies, and one surgery later, he has a diagnosis: permanent incontinence. And the cancer itself? “Clinically insignificant.” It almost certainly would never have caused him harm. He would have lived out a full life and died of something else entirely, never knowing it was there.The test didn't save his life. It changed it — for the worse.This scenario happens thousands of times a year, and it's exactly what Dr. H. Gilbert Welch — a general internist, cancer epidemiologist, and senior researcher at Brigham and Women's Hospital — spent his career warning about. His book, Should I Be Tested for Cancer?, makes a case that runs against decades of public health messaging: more testing is not automatically better testing, and early detection does not automatically mean lives saved.This article unpacks what Welch got right, where his argument leaves a gap, and what a more complete, proactive approach to cancer risk actually looks like.The Cancer Reservoir: Why Finding More Doesn't Mean Saving MoreFor decades, the operating assumption in medicine has been simple: catch cancer early, save the life. No asterisk, no nuance.Welch's research complicates that. His central idea is the cancer reservoir — the observation that most people carry small clusters of abnormal cells somewhere in their bodies right now. In the prostate, thyroid, breast, or lung. Under a microscope, these cells look like cancer. But many of them will never grow, never spread, and never threaten a life. A person could carry one for thirty years and die at 87 of heart disease, never knowing it existed.The problem is that increasingly sensitive tools — full-body scans, PSA tests, low-dose CT — are very good at finding these dormant clusters. And once something is found and labeled “cancer,” the medical system is built to treat it.Welch's numbers, drawn from randomized trial data, are striking: approximately 60% of PSA-detected prostate cancers are overdiagnosed, meaning they meet the technical definition of cancer but would never have caused symptoms or death. For mammography-detected breast cancers, the estimate is around 25% — meaning roughly one in four women treated for a screen-detected breast cancer may never have needed that treatment: the chemotherapy, the radiation, the surgery, the fear, the financial cost.This isn't an anti-medicine argument. It's a call for a conversation that rarely happens: here's the case for this test, and here's the case against it — here's what we might find that helps you, and here's what we might find that sets off a chain reaction you'll spend years managing. For most patients, that conversation never occurs.The 5-Year Survival Stat Is Misleading YouFive-year survival rates for cancer are often cited as evidence that screening works — and they sound like exactly that. But Welch shows why the number can be deceptive, and it comes down to lead-time bias.Here's the mechanism. Imagine a woman whose cancer will kill her at 65, regardless of when it's found. If screening catches it at 62, she lives three years with the diagnosis before dying at 65 — a five-year survival rate under five years. But if that same cancer isn't found until symptoms appear at 64, she lives one year with the diagnosis and dies at 65 — a five-year survival rate of zero.Same woman. Same cancer. Same date of death. But the version of her found earlier through screening appears, statistically, to have “survived longer.” Screening didn't add a single day to her life — it just moved up the start date of her diagnosis. It's the equivalent of claiming a win in a race because someone moved your starting line 200 meters ahead of everyone else's: you didn't run faster, you just started earlier. The finish line never moved.Now layer in overdiagnosis. If 1,000 people are diagnosed with cancers that would never have hurt them, and all 1,000 are alive five years later — which they would have been regardless — the survival statistics look dramatically better without a single life actually being saved. Welch's research shows that 5-year survival rates can climb while actual cancer death rates stay flat. More survivors on paper. Same number of people dying.None of this means medicine isn't making genuine progress in some cancers — colon cancer being a clear example, discussed below. It does mean that 5-year survival statistics, on their own, are not proof that a screening program is saving lives.Where the Evidence for Screening Is Actually StrongIt would be a mistake to leave this discussion thinking all screening is suspect. Welch himself is careful to draw a distinction, and there are tests with solid, randomized-trial evidence behind them.Colonoscopy for colorectal cancer is arguably the strongest case for screening that exists. It's unique because it doesn't just detect cancer — it can prevent it, by removing precancerous polyps before they ever become malignant. Colon cancer incidence and mortality have both dropped measurably in populations with high screening rates. If you're 45 or older, or have a family history, this is worth a serious conversation with your doctor.Low-dose CT for lung cancer, in high-risk individuals specifically, showed a 15–20% reduction in lung cancer deaths in the National Lung Screening Trial — but only among heavy smokers (roughly a pack a day for 20+ years). The risk-benefit math works because the baseline risk in that population is high.Cervical cancer screening — Pap smears and HPV testing — is a genuine public health success story. Rates have dropped dramatically since routine screening began, because cervical cancer has a long, slow, detectable precancerous stage that can be caught before it turns invasive.The common thread: these screenings either catch a long, slow precancerous process, or they target a population where the risk is already high enough that the math clearly favors testing. That's the question worth bringing to your doctor: given my specific risk factors, does the math on this test work in my favor?By contrast, the evidence is much weaker for consumer-marketed total-body scans, full-body MRI as a general “optimization” tool, universal PSA screening in all men over 50, and mammography in average-risk women in their 40s. These aren't mandates — they're conversations, and informed consent means understanding both sides before deciding.The Harms Nobody Talks AboutHealthcare marketing tends to present testing as one-sided: test early, catch it early, save your life. Welch's research catalogs the costs that rarely make it into that pitch.False positives. A mammogram flags a shadow. It isn't cancer — but you don't know that yet. Six weeks of follow-up imaging, maybe a biopsy, and the stress hormones flooding your body during that stretch are a real physiological cost, even when the final answer is “you're fine.”Unnecessary treatment. When a cancer that would never have caused harm is treated anyway — with surgery, radiation, or chemotherapy — the harm is real and the benefit is zero.The cancer label itself. Research shows that being labeled a cancer patient, even for a cancer that's never actively treated, changes a person's psychology, relationships, insurability, and life trajectory. Welch identifies this as a form of harm medicine rarely accounts for.Radiation exposure. Repeated CT scans carry cumulative radiation risk. A full-body scan can expose a person to the radiation equivalent of hundreds of chest X-rays — a real risk added to the body in pursuit of a cancer that may never develop.Welch's central reframe: the question isn't “should I get tested,” it's “given my risk factors, my age, my family history, and my values, does the math on this specific test work in my favor?” That's informed consent — and most people never get that conversation.The Missing Piece: Your Metabolism Is an Early Warning SystemWelch's work is thorough on what not to do. Where it leaves a gap is the proactive question: if blanket screening of healthy people isn't the answer, what is?The answer lies in the years — sometimes decades — before a tumor ever forms. Cancer doesn't appear overnight. The cellular environment that allows it to take root and grow develops gradually, and it leaves metabolic fingerprints long before any scan could detect a tumor.The clearest evidence for this comes from a 2026 study published in Nature Communications, which used machine learning on a massive UK database and linked insulin resistance to a significantly increased risk of at least 12 types of cancer. Pancreatic cancer risk was elevated by roughly 29%, colon cancer by 18%, and breast cancer by 13% — and critically, this risk showed up independent of body weight. A person at a healthy weight can still be carrying the metabolic dysfunction that drives cancer risk, and a standard annual physical would miss it entirely, because most doctors check fasting glucose, not fasting insulin. By the time glucose is elevated, insulin regulation has often been off for years.Layer in chronic inflammation (measured by hs-CRP), elevated ferritin, low vitamin D, rising homocysteine, and a poor triglyceride-to-HDL ratio, and what emerges is a picture of a metabolic environment that is increasingly hospitable to cancer. Think of it as soil: a healthy garden doesn't grow weeds easily, but depleted, imbalanced soil invites them. Cancer is the weed. Metabolic dysfunction is the depleted soil. The strategy, then, is to work on the soil rather than wait to spot the weed.What to Actually Do About ItPath A: Testing to ask your provider forThese tests build a real metabolic picture — the kind that shows soil quality before any weed appears.* Fasting insulin + HOMA-IR — not just fasting glucose. This is likely the single most important test most doctors aren't ordering.* Hemoglobin A1c — your 3-month blood sugar average.* hs-CRP — a high-sensitivity marker of systemic inflammation.* Full lipid panel, including TG/HDL ratio — a ratio above 3 is a strong metabolic red flag.* Ferritin — elevated levels are increasingly linked to inflammatory cancer environments.* Vitamin D (25-OH) — low levels are associated with higher cancer risk across multiple types; optimal is 60–80 ng/mL, not just “in range.”* Homocysteine — a methylation marker that, when elevated, signals oxidative stress.* LDH (Lactate Dehydrogenase) — rises when cells are under metabolic stress.For a deeper look, consider a comprehensive nutrient and organic acids panel (NutrEval), a gut microbiome panel (GI-MAP) — the gut-cancer connection is real — and a full hormone panel including cortisol, estrogen, testosterone, and SHBG.Path B: Lifestyle changes to start today* Eat in this order: protein and fat first, vegetables second, starches last. This alone can meaningfully blunt post-meal blood sugar spikes.* Cut refined sugars and seed oils — the two most direct dietary drivers of insulin resistance and inflammation.* Move daily. At minimum, 150 minutes of moderate activity per week, resistance training twice a week, and even a 10-minute walk after meals to improve glucose metabolism.* Prioritize sleep. Poor sleep disrupts glucose metabolism after a single bad night. Seven to nine hours is non-negotiable for metabolic health.* Manage stress. Chronic cortisol elevation drives insulin resistance — this is biochemistry, not soft advice.You don't need to do all of this at once. Pick one test to ask for at your next appointment, and one lifestyle change to start this week.Summary & Next StepDr. Welch's research makes an uncomfortable but important case: early detection is not automatically synonymous with lives saved, the 5-year survival statistic can be misleading, and testing healthy people carries real costs — false positives, unnecessary treatment, radiation exposure, and the psychological weight of a cancer label. At the same time, some screenings — colonoscopy, cervical cancer screening, low-dose CT for high-risk smokers — have strong evidence behind them and are worth pursuing for the right person.What's missing from that picture is a proactive strategy, and that's where metabolic health comes in. Insulin resistance, chronic inflammation, and blood sugar dysregulation show up years before cancer does, and unlike a full-body scan, they're both measurable and fixable.If you want a clear picture of where your own metabolic terrain stands — and what your highest-leverage next steps are — book a Metabolic Audit Call. It's a complementary 45-minute session where we review your current labs, symptoms, health history, and goals together. Spots are limited each week; the link is in the show notes.References* Welch, H.G. Should I Be Tested for Cancer? Maybe Not and Here's Why. University of California Press.* National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening.* Nature Communications (2026). Machine learning analysis of UK biobank data linking insulin resistance to increased risk across 12 cancer types, independent of body weight.* Thrive 120 Podcast, Episode 126: “Should I Be Tested for Cancer? What Dr. Welch Got Right — And What He Missed,” This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit tripleplaydoc.substack.com/subscribe

Host Dr. Celina Nahyun Jo sits down with Dr. Perry Pickhardt to explore how opportunistic CT screening is transforming routine imaging into a powerful tool for cardiometabolic risk assessment, bone health evaluation, liver disease detection, and body composition analysis. Together, they discuss the role of explainable AI, the future of CT-based biologic age, and why value-added imaging has the potential to reshape preventive care.   CT-based Opportunistic Screening for Adding Clinical Value:How I Do It. Pickhardt et al. Radiology 2026; 319(1):e252106.

Are inherited metabolic disorders more common, and less predictable, than we previously thought? Large-scale genomic studies are identifying adults with disease-associated variants who have escaped diagnosis, sometimes despite lifelong symptoms. At the same time, expanding genomic newborn screening risks identifying children who may remain well for decades or never develop clinically significant disease at all. In this episode Dr Nina Gold, Dr Jessica Gold, and Professor Mirjam Langeveld, explore the tension between missed diagnosis and overdiagnosis and ask, when does knowing more genuinely help? Are Inherited Metabolic Disorders More Common and Less Predictable Than We Thought? N Gold et al https://doi.org/10.1002/jimd.70094 Screening for Life: Perspectives From Adult Metabolic Specialists on Newborn Screening for Inherited Metabolic Diseases. M Langeveld, et al. https://doi.org/10.1002/jimd.70057 Exclusion-based exome sequencing in critically ill adults 18–40 years old has a 24% diagnostic rate and finds racial disparities in access to genetic testing. American Journal of Human Genetics J Gold et al https://www.cell.com/ajhg/fulltext/S0002-9297(25)00238-1 Long-term Penetrance of Disease Variants in Genes Prioritized for Genomic Newborn Screening. Gold NB, et al. https://www.medrxiv.org/content/10.64898/2026.06.10.26355380v1 - pre-print not peer reviewed

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-494 Overview: Primary care visits offer a valuable opportunity to identify and address excessive screen time—a health concern that can impact adults' physical and mental well-being. This episode brings you current data on adult screen use and its health consequences, helping you recognize and respond to a growing issue in patient populations. Episode resource links: Front Psychiatry. 2022 Dec 22:13:1058572. doi: 10.3389/fpsyt.2022.1058572. eCollection 2022 BMC Med. 2025 Feb 21;23(1):107. JAMA Netw Open. 2025 Mar 3;8(3):e252493. doi: 10.1001/jamanetworkopen.2025.2493 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Pentagon plans widespread testosterone screening for troops; New study claims arthroscopic surgery for age-related degenerative changes of knees is worthless; Widely touted “precision” proton therapy doesn't outperform conventional radiation treatment for prostate cancer; Comparing the effectiveness of gummies and liquids vs. tablet or capsule forms of supplements; Supplements to lower LDL; Lithium orotate for Alzheimer's prevention; Novel ultrasound treatment may target inflammation in osteoarthritis; Researchers explore antiviral treatments for multiple sclerosis.  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-494 Overview: Primary care visits offer a valuable opportunity to identify and address excessive screen time—a health concern that can impact adults' physical and mental well-being. This episode brings you current data on adult screen use and its health consequences, helping you recognize and respond to a growing issue in patient populations. Episode resource links: Front Psychiatry. 2022 Dec 22:13:1058572. doi: 10.3389/fpsyt.2022.1058572. eCollection 2022 BMC Med. 2025 Feb 21;23(1):107. JAMA Netw Open. 2025 Mar 3;8(3):e252493. doi: 10.1001/jamanetworkopen.2025.2493 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Garrett Chaffin-Quiray and Ed Rosa disagree about the rewards of found footage horror craft while noting a landmark in viral marketing.This is part of a series that overlaps with, and extends, Brian Raftery's 2020 book “Best. Movie. Year. Ever.: How 1999 Blew Up the Big Screen”. Screenings include: “Following” (Christopher Nolan, 1998), “Varsity Blues” (Brian Robbins, 1999), “The Blair Witch Project” (Daniel Myrick and Eduardo Sánchez, 1999), “The Matrix” (The Wachowskis, 1999), “Star Wars: Episode I - The Phantom Menace” (George Lucas, 1999), “South Park - Bigger, Longer and Uncut” (Trey Parker, 1999), “Free Enterprise” (Robert Meyer Burnett, 1999), “Eyes Wide Shut” (Stanely Kubrick, 1999), “Twin Falls Idaho” (Michael Polish, 1999), “American Beauty” (Sam Mendes, 1999), “Three Kings” (David O. Russell, 1999), “Boys Don't Cry” (Kimberly Peirce, 1999), “Topsy-Turvy” (Mike Leigh, 1999), “Magnolia” (Paul Thomas Anderson, 1999), and “Wadd: The Life & Times of John C. Holmes” (Cass Paley, 1998).***Referenced media:“Best. Movie. Year. Ever.: How 1999 Blew Up the Big Screen” (2020) by Brian Raftery“Psycho” (Alfred Hitchcock, 1960)“Teenage Mother” (Jerry Gross, 1967)“Stunt Rock” (Brian Trenchard-Smith, 1978)“Star Wars: The Special Edition” (George Lucas, 1977)“The Empire Strikes Back: The Special Edition” (Irvin Kershner, 1980)“Return of the Jedi: The Special Edition” (Richard Marquand, 1983)“The Witch” (Robert Eggers, 2015)“Gilligan's Island” (Sherwood Schwartz, 1964-1967)“Cloverfield” (Matt Reeves, 2008)“The Sixth Sense” (M. Night Shyamalan, 1999)“The Babadook” (Jennifer Kent, 2014)“Summer of Sam” (Spike Lee, 1999)“Jaws” (Steven Spielberg, 1975)“Lake Placid” (Steve Miner, 1999)“The Descent” (Neil Marshall, 2005)“Dog Soldiers” (Neil Marshall, 2002)“Scary Movie” (Keenen Ivory Wayans, 2000)Audio quotation:“The Blair Witch Project” (Daniel Myrick and Eduardo Sánchez, 1999), including “The Cellar” by Tony Cora“1999” (2018) written by Charlotte Aitchison, Jonnali Parmenius, Oscar Holter, Troye Sivan, Brett McLaughlin, and Max Martin, and performed by Charlie XCX and Troye Sivan, https://www.youtube.com/watch?v=ZYVtjAInQY0&list=PLQl1_YXgq4hjhZwnlRPMF-Z9aXe89WZAn&index=1“1999” (1982) written and performed by Prince, https://www.youtube.com/watch?v=rblt2EtFfC4&list=RDrblt2EtFfC4&start_radio=1“Millenium” (1998) written by Robbie Williams, Guy Chambers, Leslie Bricusse, and John Barry, and performed by Robbie Williams, https://www.youtube.com/watch?v=xcWOviMI6Lk&list=RDxcWOviMI6Lk&start_radio=1 

Kara and Scott unpack the military's new testosterone screening program, Trump's election fraud obsession, and the growing food contamination outbreak. Then, they discuss OpenAI's first AI device, IBM's stock plunge, and New York's new restrictions on data centers. Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.Send us your questions by calling us at 855-51-PIVOT, or email pivot@voxmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week in the Screening Room we’re talking about con men, deceit, stolen identities, the scene-stealing Philip Seymour Hoffman, and the 1999 film ‘The Talented Mr. Ripley.’ Plus another Hypothetical Theoretical Metaphorical Potentially Possible Mixtape with songs by Roy Orbison, Nick Lowe, Aretha Franklin, and more. Become an All Access member and get ad-free listening by visiting disgracelandpod.com.See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

Robach and Holmes cover the latest news headlines and entertainment updates and give perspective on current events in their daily “Morning Run.”See omnystudio.com/listener for privacy information.

This week in the Screening Room we’re talking about alienation, chickie runs, knife fights, and how the 1955 film ‘Rebel Without a Cause’ wound up with an X rating in the UK. Plus the mighty Hypothetical Theoretical Metaphorical Potentially Possible Mixtape with songs by The Undertones, the Flamin’ Groovies, Fountains of Wayne, and more. Become an All Access member and get ad-free listening by visiting disgracelandpod.com. Check out these other great Hollywoodland episodes on the stars of "Rebel Without a Cause:"Natalie Wood Sal Mineo Dennis Hopper What is Zeth reading this week?But Beautiful: A Book About Jazz Orson Welles, vol. 1: The Road to Xanadu See omnystudio.com/listener for privacy information.